ArmaGen Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 15

Employees

  • Latest Deal Type
  • M&A

  • Investors
  • 1

ArmaGen General Information

Description

Developer of neurological therapies headquartered in Calabasas, California. The company's pipeline of innovative therapies penetrates the blood-brain barrier to treat neurological complications of many diseases, including lysosomal storage disorders (LSDs), Alzheimer's, and Parkinson's, thereby enabling patients suffering from neurodegenerative disorders to get improved treatment.

Contact Information

Website
www.armagen.com
Formerly Known As
Neurogene Technologies, ArmaGen Technologies, Armagen Technologies Inc
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 26679 Agoura Road
  • Suite 100
  • Calabasas, CA 91302
  • United States
+1 (818)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
JCR Pharmaceuticals
Vertical(s)
Life Sciences
Corporate Office
  • 26679 Agoura Road
  • Suite 100
  • Calabasas, CA 91302
  • United States
+1 (818)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ArmaGen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Merger/Acquisition 20-Apr-2020 Completed Clinical Trials - General
7. Later Stage VC (Series A2) 01-Mar-2018 Completed Clinical Trials - General
6. Grant 01-Apr-2015 Completed Pre-Clinical Trials
5. Later Stage VC 01-Jul-2014 Completed Pre-Clinical Trials
4. Later Stage VC (Series A) 29-Nov-2012 Completed Pre-Clinical Trials
3. Debt - General 01-Jan-2012 Completed Pre-Clinical Trials
2. Grant 15-Aug-2008 $2.4M Completed Pre-Clinical Trials
1. University Spin-Out 19-Mar-2004 Completed Startup
To view ArmaGen’s complete valuation and funding history, request access »

ArmaGen Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A2
Series A1
Series A 10,616,143 $0.001000 $0.13 $1.6 $1.6 1x $1.6 24.03%
To view ArmaGen’s complete cap table history, request access »

ArmaGen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of neurological therapies headquartered in Calabasas, California. The company's pipeline of innovative therapi
Drug Discovery
Calabasas, CA
15 As of 2018

Clarksville, MD
 

Westmount, Canada
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ArmaGen Competitors (30)

One of ArmaGen’s 30 competitors is NeuroNascent, a Venture Capital-Backed company based in Clarksville, MD.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NeuroNascent Venture Capital-Backed Clarksville, MD
Angiochem Formerly VC-backed Westmount, Canada
Sangamo Therapeutics Formerly VC-backed Richmond, CA
BioCardia Formerly VC-backed Sunnyvale, CA
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
You’re viewing 5 of 30 competitors. Get the full list »

ArmaGen Patents

  • 197

    Total Documents Applications and Grants

  • Total Patents Families

  • 95

    Granted

  • 29

    Pending

  • Expiring in next 12 mo

ArmaGen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240335432-A1 Therapeutic compound for neuronal ceroid lipofuscinosis Pending 02-Sep-2021
WO-2023034553-A1 Therapeutic compound for neuronal ceroid lipofuscinosis Inactive 02-Sep-2021
EP-3908611-A1 Methods and compositions for increasing galactosidase beta-1 activity in the cns Inactive 08-Jan-2019
EP-3908611-A4 Methods and compositions for increasing galactosidase beta-1 activity in the cns Inactive 08-Jan-2019
US-20210403584-A1 Methods and compositions for increasing galactosidase beta-1 activity in the cns Inactive 08-Jan-2019 C12N9/2471
To view ArmaGen’s complete patent history, request access »

ArmaGen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ArmaGen Former Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Boehringer Ingelheim Venture Fund Corporate Venture Capital Minority
Michael J. Fox Foundation Limited Partner
Mitsui Global Investment Venture Capital Minority
Shire (Pharmaceuticals) Corporation Minority
Takeda Ventures Corporate Venture Capital Minority
You’re viewing 5 of 6 investors. Get the full list »

Ready to get started?

Request a free trial

ArmaGen FAQs

  • When was ArmaGen founded?

    ArmaGen was founded in 2004.

  • Where is ArmaGen headquartered?

    ArmaGen is headquartered in Calabasas, CA.

  • What is the size of ArmaGen?

    ArmaGen has 15 total employees.

  • What industry is ArmaGen in?

    ArmaGen’s primary industry is Drug Discovery.

  • Is ArmaGen a private or public company?

    ArmaGen is a Private company.

  • What is ArmaGen’s current revenue?

    The current revenue for ArmaGen is .

  • How much funding has ArmaGen raised over time?

    ArmaGen has raised $52M.

  • Who are ArmaGen’s investors?

    Boehringer Ingelheim Venture Fund, Michael J. Fox Foundation, Mitsui Global Investment, Shire (Pharmaceuticals), and Takeda Ventures are 5 of 6 investors who have invested in ArmaGen.

  • Who are ArmaGen’s competitors?

    NeuroNascent, Angiochem, Sangamo Therapeutics, BioCardia, and Inovio Pharmaceuticals are some of the 30 competitors of ArmaGen.

  • When was ArmaGen acquired?

    ArmaGen was acquired on 20-Apr-2020.

  • Who acquired ArmaGen?

    ArmaGen was acquired by JCR Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process